This site is intended only for healthcare professionals resident in the Republic of Ireland
BESPONSA is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).1
The efficacy and safety of BESPONSA were evaluated in a Phase 3 clinical trial vs standard chemotherapy.1,2
Review the safety profile of BESPONSA.1
Besponsa is a 1-hour IV infusion and can conveniently be administered in the outpatient setting.1,3
Legal Category: S1A
Further information is available upon request
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023